In the long search for answers to one of medicine's most unforgiving cancers, researchers at the University of Pennsylvania have found an unlikely candidate in a seventy-year-old blood pressure pill that costs less than a cup of coffee. Hydralazine, already trusted by millions to quiet their arteries, appears to disrupt the very survival mechanism that allows glioblastoma to thrive in the oxygen-starved terrain it creates for itself. The discovery is still confined to the laboratory, but in a disease where half of patients are gone within fourteen months, even a whisper of a new path carries t
Daily Mail Online
· Nov 17, 2025
· health
· 3 min read
Medium
Sourcing: Characterized
Cheap blood pressure drug shows promise against deadly brain cancer in early study
Glioblastoma affects approximately 12,000 people annually in the US with only 5% five-year survival rate and 50% mortality within 14 months of diagnosis.
◉
Health & Medicine
7710 related articles
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 100% match
French hantavirus patient in critical condition on artificial lung as …
CBC.ca · 99% match
French hantavirus patient on life support as cruise outbreak reaches 1…
PerthNow · 99% match
French hantavirus patient on artificial lung as cruise outbreak reache…
South China Morning Post · 99% match
French hantavirus patient critically ill on artificial lung as cruise …
Chicago Tribune · 99% match
Related Coverage
BBC News · Aug 14
NHS admits transplant patient data sent over unencrypted pagers
NHS Blood and Transplant admitted to sending sensitive patient data including names and organ types over unencrypted pag…
Fox News · Aug 14 HHS Report Features Detransitioners' Accounts of Pressure for Gender TreatmentsAn HHS-commissioned report features three detransitioners alleging doctors pressured them into gender transition treatme…
Nature · Aug 14 Optimized iNKT cell therapy shows promise against multiple myelomaResearchers optimized CAR-iNKT cell immunotherapy for multiple myeloma treatment, finding CD28z CAR-iNKT cells outperfor…
Google News · Aug 14 Taylor Frankie Paul's Ex Seeks to Unseal Drug Test Results in CourtTaylor Frankie Paul's ex-husband Tate has filed a court request to unseal drug test results, likely related to custody o…
Bias & Framing
⚖
Article presents early-stage research optimistically with emphasis on drug's low cost and age, using hopeful framing while acknowledging limited evidence.
Bias Direction
center-right
Confidence
MED
Positive sensationalism with cost-benefit emphasis. The article leads with 'promise' and 'hope' while burying the 'very early stages' caveat. Emphasis on the drug's cheapness ($0.33) and age (70 years old) creates a 'miracle cure' narrative appealing to cost-conscious readers.
deadly brain cancer
one of the deadliest
kills half of patients
potential sign of hope
unusual links that could spell new solutions
teaching us something new
Oncologist skepticism about translating lab results to human trials
Historical context of failed early-stage cancer drug discoveries
Patient advocacy group perspectives on realistic timelines
Pharmaceutical industry commentary on drug repurposing economics
Competing or alternative glioblastoma research approaches
Limitations of in vitro lab testing for brain cancer treatments
Geopolitical Impact
🌎
Medical research discovery has no direct geopolitical implications; this is a domestic healthcare/scientific advancement with potential global humanitarian benefits.
Escalation Risk
low
Confidence
HIGH
No power dynamics shifts. This is a scientific advancement that could benefit all nations equally if validated and scaled.
Economic Lens
📈
Early-stage research suggests repurposing a 70-year-old $0.33 blood pressure drug (hydralazine) may combat glioblastoma, potentially creating low-cost treatment options but requiring extensive clinical validation before market impact.
Market Signal
mixed
Confidence
LOW
Pharmaceutical manufacturing
Oncology/cancer treatment
Healthcare services
Medical research and development
Generic drug production
Potential long-term benefit for glioblastoma patients through affordable repurposed medication, but immediate consumer impact is minimal as research is in early stages. Could reduce treatment costs if clinical trials succeed, benefiting patients and reducing healthcare expenditures.
May incentivize FDA fast-track approval pathways for drug repurposing. Could influence pharmaceutical pricing policies and R&D incentives for generic drug applications. May prompt increased funding for translational research linking existing medications to new disease indications.